# MOLINNO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molinno

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Total disclosed funding: $0.1M
- Latest round: Seed (Apr 26, 2024)
- Investors on record: 1

## About

Based in Seoul, South Korea, and founded in 2021 by CEO Hanshin Hwang and CTO Eunhak Lim, Molecular Innovations doing business as Molinno operates as a Healthtech company providing drugs and raw materials for health foods and cosmetics, using molecular-weight substances modified by resveratrol. In April 2024, MOLINNO raised KRW 200 million in seed funding from Seoul Technology Holdings. 

Molecular Innovations developed molecular-weight substance which is a cardiovascular protection, anti-cancer, and anti-inflammatory for the food and cosmetic industries. The company’s product focuses on skin treatment and skin improvement.

## Funding rounds

- Seed, Apr 26, 2024, $0.1M — Seoul Technology Holdings

## Investors

- Seoul Technology Holdings (https://capitalatlas.ai/funds/seoul-technology-holdings) — Seed